| Literature DB >> 36003352 |
Tasneem Siddiqui1, Sangram Singh Patel1, Richa Sinha1, Ujjala Ghoshal1, Chinmoy Sahu1.
Abstract
Introduction: Ralstonia mannitolilytica is a rare opportunistic pathogen capable of causing a serious infection in immunocompromised patients. Our objective was to describe all cases of R. mannitolilytica bloodstream infection identified within 2 years at our tertiary care centre, focusing on clinical characteristics, risk factors, antibiotic sensitivity patterns, management and outcomes. Case Series: We compiled a descriptive case series including 14 non-duplicate R. mannitolilytica isolates obtained from bloodstream infection samples from the microbiology laboratory of a tertiary care centre from June 2019 to June 2021. All isolates were initially identified based on their morphological properties and biochemical reactions, and then underwent matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) examination for confirmation of identity. Antibiotic susceptibility testing was performed using the Kirby-Bauer disc diffusion method and Vitek 2. All 14 patients presented with symptoms of fever and/or chills, and a positive blood culture for R. mannitolilytica . After 48 h of incubation, no Ralstonia growth was reported from any of the current environmental or pharmaceutical water samples. Chemotherapy (9/14), mechanical ventilation (4/14), steroid use (2/14) and diabetes mellitus (1/14) were associated risk factors in our patients. The antibiotic sensitivity panel showed maximum resistance to aminoglycosides (64.3%) and no resistance to cefoperazone/sulbactum. Patients received treatment with cefoperazone/sulbactum and meropenem or ceftazidime. Thirteen patients recovered with antibiotic therapy and one patient succumbed to his illness.Entities:
Keywords: Gram-negative; MALDI-TOF-MS; Ralstonia mannitolilytica; nosocomial pathogen
Year: 2022 PMID: 36003352 PMCID: PMC9394538 DOI: 10.1099/acmi.0.000367
Source DB: PubMed Journal: Access Microbiol ISSN: 2516-8290
Demographic and clinical characteristics of patients
|
Patient no. |
Age range |
Clinical diagnosis |
Risk factors |
|---|---|---|---|
|
1 |
21–30 |
Dengue haemorrhagic shock syndrome |
Gastrointestinal surgery within 30 days, mechanical ventilation, steroid use |
|
2 |
51–60 |
Decompensated chronic liver disease |
Diabetes mellitus |
|
3 |
51–60 |
Acute respiratory distress syndrome |
Mechanical ventilation, anti-tubercular treatment |
|
4 |
31–40 |
Acute necrotizing pancreatitis |
Mechanical ventilation |
|
5 |
11–20 |
Acute lymphoblastic leukaemia |
Chemotherapy |
|
6 |
51–60 |
Severe COVID-19 pneumonia |
Mechanical ventilation, steroids |
|
7 |
11–20 |
Acute myeloid leukaemia |
Chemotherapy |
|
8 |
51–60 |
Breast carcinoma |
Chemotherapy |
|
9 |
11–20 |
Acute myeloid leukaemia |
Chemotherapy |
|
10 |
1–10 |
Hodgkin’s lymphoma |
Chemotherapy |
|
11 |
11–20 |
Hodgkin’s lymphoma |
Chemotherapy |
|
12 |
11–20 |
Acute myeloid leukaemia |
Chemotherapy |
|
13 |
11–20 |
Acute lymphoblastic leukaemia |
Chemotherapy |
|
14 |
11–20 |
Acute myeloid leukaemia |
Chemotherapy |
Fig. 1.Antimicrobial susceptibility of 14 clinical isolates of determined using the CLSI standards and interpreted as per the CLSI breakpoints for spp.
Timeline of infection, identification, management and outcome for the patients
|
Patient no. |
Duration of hospital stay (days) |
Time from admission to development of infection (days) |
Identity of isolates (MALDI-TOF) |
Treatment received |
Outcome/follow-up |
|---|---|---|---|---|---|
|
1 |
11 |
5 |
|
Cefoperazone/sulbactum |
Recovered |
|
2 |
15 |
11 |
|
Cefoperazone/sulbactum |
Recovered |
|
3 |
58 |
27 |
|
Cefoperazone/sulbactum |
Recovered |
|
4 |
35 |
5 |
|
Cefoperazone/sulbactum |
Recovered |
|
5 |
10 |
8 |
|
Meropenem+colistin |
Recovered |
|
6 |
49 |
26 |
|
Meropenem+colistin |
Dead |
|
7 |
20 |
8 |
|
Cefoperazone/sulbactum |
Recovered |
|
8 |
10 |
6 |
|
Meropenem+colistin |
Recovered |
|
9 |
21 |
6 |
|
Cefoperazone/sulbactum |
Recovered |
|
10 |
40 |
30 |
|
Cefoperazone/sulbactum |
Recovered |
|
11 |
29 |
25 |
|
Cefoperazone/sulbactum |
Recovered |
|
12 |
52 |
32 |
|
Ceftazidime+amikacin |
Recovered |
|
13 |
31 |
12 |
|
Cefoperazone/sulbactum |
Recovered |
|
14 |
28 |
10 |
|
Cefoperazone/sulbactum |
Recovered |